IL7R α-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)

The National Cancer Institute seeks licensing and/or co-development research collaborations for further development of antibodies that selectively target IL-7R α, a major driver of T-cell derived ALL (T-ALL) and an important therapeutic target for a range of diseases.NIH Ref. No.: E-247-2015Advantages: Selectively bind IL-7R α with high (nanomolar) affinityMediates cancer cell killing through antibody-dependent cellular cytotoxicity (ADCC)Targeted therapy with potential for fewer and less severe adverse eventsWell-established regulatory pathNumerous approved products using same approach (e.g., Rituximab, and Cetuximab)Applications: Targeted therapy for various cancers including T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL)Targeted therapy for several autoimmune disorders (Type 1 diabetes and multiple sclerosis), organ transplant rejection,  Type 1 diabetes, and multiple sclerosisDevelopment Status: Pre-clinical (in vivo)Updated On: Jan 17, 2018Date Published: Thursday, December 7, 2017Provider Classifications: Patent Application: 62/238,612PCT/US2016/055957Publications: Licensing Contacts: Lead Inventor: Inventor Lab URL: https://ccr.cancer.gov/Cancer-and-Inflammation-Program/scott-k-durumInv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: TherapeuticsDTDT Description: TherapeuticsPat Filing Date: 2015-10-...

Source: NIH OTT Licensing Opportunities - December 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research